Direct-to-Consumer Genetic Testing Market Size to Grow by USD 1.38 billion | 23andMe Inc. and Alpha Biolaboratories Ltd. Among Key Vendors | Technavio
NEW YORK, July 1, 2022 /PRNewswire/ -- The direct-to-consumer genetic testing market is fragmented, and the vendors are deploying growth strategies such as market expansion, investments, and distribution networks to compete in the market.
The direct-to-consumer genetic testing market size is anticipated to grow by USD 1.38 bn from 2020 to 2025. Moreover, the growth momentum of the market will accelerate at a CAGR of 16.37% during the forecast period.
The growing adoption of direct-to-consumer genetic testing in early disease diagnosis is driving the growth of the direct-to-consumer genetic testing market. However, factors such as doubts over analytical and clinical validity may challenge the market growth during the forecast period.
Company Profiles
The direct-to-consumer genetic testing market report provides complete insights on key vendors, including 23andMe Inc., Alpha Biolaboratories Ltd., Centrillion Technology Holdings Ltd., Color Genomics Inc., Dante Labs Inc., DNA Diagnostic Center Inc., Full Genomes Corp., Laboratory Corp. of America Holdings, Myriad Genetics Inc., and Quest Diagnostics Inc. The key offerings of some of the vendors are listed below:
23andMe Inc. - The company offers high-quality advanced direct-to-consumer genetic testing services.
Alpha Biolaboratories Ltd. - The company provides a comprehensive range of direct-to-consumer genetic testing to its consumers, such as Paternity testing, Legal DNA testing, Immigration DNS testing, Aunt test, Grandparents test and others.
Centrillion Technology Holdings Ltd. - The company offers direct-to-consumer genetic testing across the globe.
Color Genomics Inc. - The company offers direct-to-consumer genetic testing across the globe to consumers.
Dante Labs Inc. - The company offers its direct-to-consumer genetic testing services to its consumers.
Competitive Analysis
The competitive scenario provided in the direct-to-consumer genetic testing market report analyzes, evaluates, and positions companies based on various performance indicators. Some of the factors considered for this analysis include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, growth in market share, etc.
Market Segmentation
By distribution channel, the market is classified into direct sales and retail sales. The direct sales segment will contribute the largest share of the market. Direct sales channels give consumers access to their personal genetic and health information, regardless of the time and place. The test orders, results, and health information are maintained on a centralized network containing personal health records. Many consumers are purchasing genetic testing services through direct sales channels, owing to the quick turnaround time in obtaining results as well as the increasing Internet penetration. This has fueled the demand for online orders of genetic tests, thus boosting revenue growth in the direct sales segment.
By service, the market has been segmented into diagnostic screening, prenatal, newborn screening, and pre-implantation diagnosis, and relationship testing.
By geography, the market is classified as North America, Europe, Asia, ROW, North America, Europe, Asia, and ROW. North America will have the largest share of the market.
North America, Europe, Asia, ROW, North America, Europe, Asia, and ROW
Performing market contribution
North America at 39%
Key consumer countries
US, UK, Germany, France, and Japan
Competitive landscape
Leading companies, competitive strategies, consumer engagement scope
Companies profiled
23andMe Inc., Alpha Biolaboratories Ltd., Centrillion Technology Holdings Ltd., Color Genomics Inc., Dante Labs Inc., DNA Diagnostic Center Inc., Full Genomes Corp., Laboratory Corp. of America Holdings, Myriad Genetics Inc., and Quest Diagnostics Inc.
Market Dynamics
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and future consumer dynamics, market condition analysis for forecast period,
Customization purview
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.
Table of Contents
1 Executive Summary
2 Market Landscape
2.1 Market ecosystem
Exhibit 01: Parent market
Exhibit 02: Market characteristics
Exhibit 03: Value chain analysis: Life Sciences Tools and Services
2.2 Value chain analysis
3 Market Sizing
3.1 Market definition
Exhibit 05: Market segments
3.2 Market segment analysis
3.3 Market size 2020
3.4 Market outlook: Forecast for 2020 - 2025
Exhibit 06: Global - Market size and forecast 2020 - 2025 ($ million)
Exhibit 07: Global market: Year-over-year growth 2020 - 2025 (%)
4 Five Forces Analysis
4.1 Bargaining power of buyers
Exhibit 09: Bargaining power of buyers
4.2 Bargaining power of suppliers
Exhibit 10: Bargaining power of suppliers
Exhibit 11: Threat of new entrants
4.3 Threat of new entrants
4.4 Threat of substitutes
Exhibit 12: Threat of substitutes
4.5 Threat of rivalry
Exhibit 13: Threat of rivalry
Exhibit 14: Market condition - Five forces 2020
4.6 Market condition
5 Market Segmentation by Distribution channel
5.1 Market segments
Exhibit 16: Comparison by Distribution channel
5.2 Comparison by Distribution channel
Exhibit 17: Direct sales - Market size and forecast 2020-2025 ($ million)
5.3 Direct sales - Market size and forecast 2020-2025
Exhibit 18: Direct sales - Year-over-year growth 2020-2025 (%)
Exhibit 61: Color Genomics Inc. - Product and service
11.6 Color Genomics Inc.
Exhibit 62: Color Genomics Inc. - Key offerings
Exhibit 63: Dante Labs Inc. - Overview
Exhibit 64: Dante Labs Inc. - Product and service
Exhibit 65: Dante Labs Inc. - Key offerings
11.7 Dante Labs Inc.
Exhibit 66: DNA Diagnostic Center Inc. - Overview
Exhibit 67: DNA Diagnostic Center Inc. - Product and service
11.8 DNA Diagnostic Center Inc.
Exhibit 68: DNA Diagnostic Center Inc. - Key offerings
Exhibit 69: Full Genomes Corp. - Overview
Exhibit 70: Full Genomes Corp. - Product and service
Exhibit 71: Full Genomes Corp. - Key offerings
11.9 Full Genomes Corp.
Exhibit 72: Laboratory Corp. of America Holdings - Overview
Exhibit 73: Laboratory Corp. of America Holdings - Business segments
11.10 Laboratory Corp. of America Holdings
Exhibit 74: Laboratory Corp. of America Holdings - Key offerings
Exhibit 75: Laboratory Corp. of America Holdings - Segment focus
Exhibit 76: Myriad Genetics Inc. - Overview
Exhibit 77: Myriad Genetics Inc. - Business segments
11.11 Myriad Genetics Inc.
Exhibit 78: Myriad Genetics Inc. - Key news
Exhibit 79: Myriad Genetics Inc. - Key offerings
Exhibit 80: Myriad Genetics Inc. - Segment focus
Exhibit 81: Quest Diagnostics Inc. - Overview
Exhibit 82: Quest Diagnostics Inc. - Business segments
Exhibit 83: Quest Diagnostics Inc. - Key offerings
11.12 Quest Diagnostics Inc.
Exhibit 84: Quest Diagnostics Inc. - Segment focus
12 Appendix
12.1 Scope of the report
Exhibit 85: Currency conversion rates for US$
12.2 Currency conversion rates for US$
Exhibit 86: Research Methodology
12.3 Research methodology
Exhibit 87: Validation techniques employed for market sizing
Exhibit 88: Information sources
Exhibit 89: List of abbreviations
12.4 List of abbreviations
About Us
Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provide actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
AIDS Healthcare Foundation applauds the government of Colombia for issuing a compulsory license on HIV drug dolutegravir, which will allow the country to access affordable generic versions of the treatment as an alternative to the costly branded...
BCACC is pleased to announce that its Deputy Registrar, Kathy Lauriente, has been honoured with the Distinguished Service Award from Thompson Rivers University. The award recognizes stellar contributions to the University, community, and the public...
The scheduled merits hearing dates, April 26 and 29, 2024, in the above-named matter will proceed by videoconference.
On April 26, 2024, the hearing will commence 11:15 a.m.
Members of the public may observe the hearing by videoconference, by...
Valeo Pharma Inc. ("Valeo" or the "Company"), a Canadian pharmaceutical company, today announced the results of the matters submitted to shareholders at its annual meeting of shareholders held on April 25, 2024 (the "Meeting")....
Community Healthcare Trust Incorporated today announced that its Board of Directors has increased its common stock cash dividend for the quarter ended March 31, 2024. This dividend, in the amount of $0.46 per share, is payable on May 24, 2024 to...